Literature DB >> 10398357

Drug treatment of older people with affective disorders in the community: lessons from an attempted clinical trial.

T Stevens1, C Katona, M Manela, V Watkin, G Livingston.   

Abstract

BACKGROUND: Depression and phobic anxiety disorders are the most common psychiatric disorders in people aged 65 and over. SSRI antidepressants are effective in treating both conditions in younger people, and in treating depression in hospital samples of older subjects. No studies have investigated the efficacy of SSRIs in older people with these conditions living in the community.
OBJECTIVES: To evaluate the efficacy and feasibility of treating older people suffering from depression and/or phobic anxiety in the community with fluoxetine alone.
DESIGN: Subjects identified as depressed and/or anxious at screening were offered open-label fluoxetine and were reassessed for affective illness at 3 and 6 months. MEASURES: Outcome was assessed using the depression subscale of the Short Comprehensive Assessment and Referral Evaluation (Short-CARE) Scale and the Anxiety Disorder Scale.
RESULTS: Of 67 subjects with depression and/or phobic anxiety, 55 (81%) were eligible to take fluoxetine. Fifty-four (98%) of these agreed to follow-up but only six (11%) agreed to take medication. No subject was still taking medication by the end of the study. Among those subjects on whom follow-up data were available, 70% of subjects depressed at screening and 97% of those with phobic anxiety retained their diagnoses at 3 months; at 6 months, the figures were 65% and 92% respectively.
CONCLUSIONS: Drug treatment alone is not acceptable to older patients in the community with depression and phobic anxiety disorders. Discussion of symptoms with an appropriate professional is insufficient therapy on its own. Further work is needed to evaluate the effectiveness of a key worker such as a mental health nurse in coordinating treatment of patients with these disorders. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398357     DOI: 10.1002/(sici)1099-1166(199906)14:6<467::aid-gps956>3.0.co;2-z

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  6 in total

1.  Evaluating a mental health assessment for older people with depressive symptoms in general practice: a randomised controlled trial.

Authors:  Antony J Arthur; Carol Jagger; James Lindesay; Ruth J Matthews
Journal:  Br J Gen Pract       Date:  2002-03       Impact factor: 5.386

2.  Personal characteristics and depression-related attitudes of older adults and participation in stages of implementation of a multi-site effectiveness trial (PRISM-E).

Authors:  Marsha N Wittink; David Oslin; Kathryn A Knott; James C Coyne; Joseph J Gallo; Cynthia Zubritsky
Journal:  Int J Geriatr Psychiatry       Date:  2005-10       Impact factor: 3.485

3.  Patient characteristics associated with participation in a practice-based study of depression in late life: the Spectrum study.

Authors:  Joseph J Gallo; Hillary R Bogner; Joseph B Straton; Katherine Margo; Pat Lesho; Peter V Rabins; Daniel E Ford
Journal:  Int J Psychiatry Med       Date:  2005       Impact factor: 1.210

4.  Intent-to-Treat vs. Non-Intent-to-Treat Analyses under Treatment Non-Adherence in Mental Health Randomized Trials.

Authors:  Thomas R Ten Have; Sharon-Lise T Normand; Sue M Marcus; C Hendricks Brown; Philip Lavori; Naihua Duan
Journal:  Psychiatr Ann       Date:  2008-12

5.  Personal characteristics of older primary care patients who provide a buccal swab for apolipoprotein E testing and banking of genetic material: the spectrum study.

Authors:  Hillary R Bogner; Marsha N Wittink; Jon F Merz; Joseph B Straton; Peter F Cronholm; Peter V Rabins; Joseph J Gallo
Journal:  Community Genet       Date:  2004

6.  Pilot testing a model of psychological care for heart transplant recipients.

Authors:  Aaron Conway; Judith Sheridan; Joanne Maddicks-Law; Paul Fulbrook
Journal:  BMC Nurs       Date:  2016-10-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.